Encore Dermatology, Inc., a Malvern, Pennsylvania-based dermatologically-focused specialty pharmaceutical company, received a $20m venture loan facility from Horizon Technology Finance Corporation (NASDAQ: HRZN).
$15m out of the total financing has been initially funded.
The capital will enable the company to acquire three commercial dermatological products to add to its portfolio to help customers treat skin diseases such as psoriasis, atopic dermatitis and acne and conduct its strategic corporate purposes.
Led by Bob Moccia, President and Chief Executive Officer, Encore Dermatology has primary focus on topical corticosteroids available via prescription to treat a variety of skin conditions.
The company is backed by investors including EW Healthcare Partners (formerly known as Essex Woodlands), 1315 Capital and Longitude Capital.